The FINEARTS-HF trial showed a 16% relative risk reduction in the composite outcome of cardiovascular death and total heart failure events in patients with LVEF ≥40%. How meaningful is this result in the context of current treatment options for heart failure with preserved or mildly reduced ejection fraction, which is notoriously difficult to treat?

The primary endpoint results were consistent across all prespecified subgroups. Can you elaborate on why this consistency is crucial for validating KERENDIA's efficacy in a broad range of heart failure patients, and how it may influence treatment guidelines?

KERENDIA also showed a significant reduction in total worsening heart failure events and improvement in patient-reported health status through the Kansas City Cardiomyopathy Questionnaire (KCCQ). Can you explain the importance of these secondary outcomes in assessing the real-world impact of finerenone on patient quality of life?

No new safety signals were identified in the FINEARTS-HF trial, and hyperkalemia was more common but rarely led to hospitalization. How does KERENDIA’s safety profile compare to existing treatments for heart failure, and what precautions might clinicians need to take in monitoring patients?

Many patients in the FINEARTS-HF trial had comorbid conditions like obesity, hypertension, and chronic kidney disease. How significant are the trial’s results in addressing the complex needs of these patients, and does finerenone offer advantages in managing multiple cardiovascular risk factors?

KERENDIA is the first non-steroidal mineralocorticoid receptor antagonist to demonstrate cardiovascular benefit in heart failure patients with LVEF ≥40%. How does this distinguish it from steroidal MRAs like spironolactone, and could this potentially change the therapeutic landscape for heart failure treatment?

Given KERENDIA's established benefits in reducing cardiovascular events in patients with chronic kidney disease associated with type 2 diabetes, how do the FINEARTS-HF findings expand its potential use in a broader cardiovascular population beyond just those with kidney disease?

With Bayer planning to submit regulatory filings based on the FINEARTS-HF data, what are the most important considerations for securing approval, and how do you envision finerenone being integrated into clinical practice for heart failure patients with preserved or mildly reduced ejection fraction?